{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T04:21:03Z","timestamp":1773375663358,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T00:00:00Z","timestamp":1625961600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hyperkalaemia is a frequent and potentially life-threatening condition in patients with chronic kidney disease (CKD). Even after successful kidney transplantation (KTx), KTx recipients have mild to severe CKD. Moreover, they share comorbid conditions and frequently use medications that predispose to hyperkalaemia. This study aimed to examine the prevalence and factors associated with hyperkalaemia in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Over a pre-specified period of 6 months (1 September 2019 to 31 March 2020), we recorded in cross-sectional fashion information on serum potassium (K+) and relevant demographics, comorbidities, medications, laboratory and transplant-associated variables in clinically stable KTx recipients attending the Transplant Outpatient Clinic of our Department. \u0397yperkalaemia was classified as follows: serum K+ level &amp;gt;5.0 mEq\/L; and further as &amp;gt;5.0 mEq\/L with concomitant use of sodium (Na+) polystyrene sulphonate; serum K+ \u22655.2 mEq\/L; serum K+ \u22655.5 mEq\/L. Univariate and multiple logistic regression analyses were used to identify factors associated with serum K+ &amp;gt;5.0 mEq\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study population consisted of 582 stable KTx recipients, 369 (63.4%) males, aged 52.4 \u00b1 13.5 years, with estimated glomerular filtration rate (eGFR) of 55.8 \u00b1 20.1 mL\/min\/1.73 m2 transplanted for &amp;gt;1 year. The prevalence of hyperkalaemia defined as K+ &amp;gt;5.0 mEq\/L; &amp;gt;5.0 mEq\/L and use of Na+ polystyrene sulphonate; K+ \u22655.2; or K+ \u22655.5 mEq\/L, was: 22.7, 22.7, 14.4 and 4.1% (132, 132, 84 and 24 patients), respectively. In multivariate analysis, male gender [odds ratio (OR) = 2.020, 95% confidence interval (CI) 1.264\u20133.227] and use of renin\u2013angiotensin\u2013aldosterone system (RAAS) blockers (OR = 1.628, 95% CI 1.045\u20132.536) were independently associated with hyperkalaemia, while higher eGFR (OR = 0.967, 95% CI 0.955\u20130.979) and use of non-K+-sparing diuretics (OR = 0.140, 95% CI 0.046\u20130.430) were associated with lower odds of the disorder.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The prevalence of mild hyperkalaemia in stable KTx recipients is relatively high but that of moderate or severe hyperkalaemia is low. Among a wide range of factors studied, only male gender and RAAS blockade were associated with increased odds of hyperkalaemia, while higher eGFR and diuretics were associated with decreased odds of hyperkalaemia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfab129","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T11:20:50Z","timestamp":1625656850000},"page":"43-50","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence and factors associated with hyperkalaemia in stable kidney transplant recipients"],"prefix":"10.1093","volume":"15","author":[{"given":"Maria","family":"Smyrli","sequence":"first","affiliation":[{"name":"Department of Nephrology, General Hospital of Euaggelismos, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4018","authenticated-orcid":false,"given":"Pantelis A","family":"Sarafidis","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hippokration Hospital, Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-4176","authenticated-orcid":false,"given":"Charalampos","family":"Loutradis","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hippokration Hospital, Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Korogiannou","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Renal Transplantation, Laiko General Hospital, National and Kapodistrian University, Medical School of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis N","family":"Boletis","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Renal Transplantation, Laiko General Hospital, National and Kapodistrian University, Medical School of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smaragdi","family":"Marinaki","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology and Renal Transplantation, Laiko General Hospital, National and Kapodistrian University, Medical School of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,10]]},"reference":[{"key":"2022031114542512100_sfab129-B1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1681\/ASN.V981535","article-title":"Hyperkalemia: a potential silent killer","volume":"9","author":"Weiner","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"2022031114542512100_sfab129-B2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/j.ajkd.2010.01.020","article-title":"A physiologic-based approach to the evaluation of a patient with hyperkalemia","volume":"56","author":"Palmer","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2022031114542512100_sfab129-B3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/archinte.158.8.917","article-title":"Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines","volume":"158","author":"Acker","year":"1998","journal-title":"Arch Intern Med"},{"key":"2022031114542512100_sfab129-B4","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2215\/CJN.01150112","article-title":"Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic","volume":"7","author":"Sarafidis","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031114542512100_sfab129-B5","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"2022031114542512100_sfab129-B6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol"},{"key":"2022031114542512100_sfab129-B7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0002-9343(00)00496-4","article-title":"Drug-induced hyperkalemia: old culprits and new offenders","volume":"109","author":"Perazella","year":"2000","journal-title":"Am J Med"},{"key":"2022031114542512100_sfab129-B8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000442393","article-title":"Prevalence of hyperkalemia in diabetic and non-diabetic patients with chronic kidney disease: a nested case-control study","volume":"42","author":"Loutradis","year":"2015","journal-title":"Am J Nephrol"},{"key":"2022031114542512100_sfab129-B9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","author":"Weir","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031114542512100_sfab129-B10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/11316430-000000000-00000","article-title":"ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized?","volume":"27","author":"Pappoe","year":"2010","journal-title":"Drugs Aging"},{"key":"2022031114542512100_sfab129-B11","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1517\/14656566.2015.1083977","article-title":"Advances in treatment of hyperkalemia in chronic kidney disease","volume":"16","author":"Sarafidis","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2022031114542512100_sfab129-B12","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"2022031114542512100_sfab129-B13","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/j.1600-6143.2004.00573.x","article-title":"Kidney transplantation Halts cardiovascular disease progression in patients with end-stage renal disease","volume":"4","author":"Meier-Kriesche","year":"2004","journal-title":"Am J Transplant"},{"key":"2022031114542512100_sfab129-B14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fmed.2018.00261","article-title":"Electrolyte and acid-base disorders in the renal transplant recipient","volume":"5","author":"Pochineni","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"2022031114542512100_sfab129-B15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/17843286.2018.1549193","article-title":"Electrolytes disturbances after kidney transplantation","volume":"74","author":"De Waele","year":"2019","journal-title":"Acta Clin Belg"},{"key":"2022031114542512100_sfab129-B16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ndt\/gfg515","article-title":"Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities","volume":"19","author":"Higgins","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2022031114542512100_sfab129-B17","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/ndt\/gfl211","article-title":"Complete renal tubular acidosis late after kidney transplantation","volume":"21","author":"Schwarz","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2022031114542512100_sfab129-B18","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/ndt\/gfm864","article-title":"ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations","volume":"23","author":"Mitterbauer","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2022031114542512100_sfab129-B19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022031114542512100_sfab129-B20","doi-asserted-by":"crossref","first-page":"F499","DOI":"10.1152\/ajprenal.90489.2008","article-title":"The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins","volume":"297","author":"Mohebbi","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031114542512100_sfab129-B21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trre.2016.10.006","article-title":"Immunosuppression for kidney transplantation: where are we now and where are we going?","volume":"31","author":"Lim","year":"2017","journal-title":"Transplant Rev (Orlando)"},{"key":"2022031114542512100_sfab129-B22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.12659\/AOT.889858","article-title":"Effect of different tacrolimus levels on early outcomes after kidney transplantation","volume":"19","author":"Andreoni","year":"2014","journal-title":"Ann Transplant"},{"key":"2022031114542512100_sfab129-B23","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ejim.2009.07.002","article-title":"eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population","volume":"20","author":"Drion","year":"2009","journal-title":"Eur J Intern Med"},{"key":"2022031114542512100_sfab129-B24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications","volume":"20","author":"Moranne","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2022031114542512100_sfab129-B25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1532-5415.2011.03818.x","article-title":"Metabolic complications in elderly adults with chronic hidney disease","volume":"60","author":"Drawz","year":"2012","journal-title":"J Am Geriatr Soc"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfab129\/40078577\/sfab129.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/1\/43\/42843269\/sfab129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/1\/43\/42843269\/sfab129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T14:55:02Z","timestamp":1647010502000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/15\/1\/43\/6319021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,7,10]]},"published-print":{"date-parts":[[2022,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfab129","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1]]},"published":{"date-parts":[[2021,7,10]]}}}